Its subsidiary’s Class 1 innovative drug TQB3205 has been approved for clinical trials, intended for the treatment of advanced malignant tumors.
March 12, 2026
Source: drugdu
36
On March 11, China Biopharmaceutical (01177) issued an announcement stating that its subsidiary, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., has independently developed a Class 1 innovative drug.TQB3205 has received clinical trial approval from the China National Medical Products Administration and is intended for the treatment of advanced malignant tumors.
TQB3205 is an oral pan-KRAS inhibitor that effectively inhibits the proliferation of various KRAS-mutated tumor cells. The company will accelerate the clinical development of TQB3205, aiming to overcome existing treatment limitations and bring new treatment options to a wider range of patients with KRAS-mutated advanced malignancies.
https://finance.eastmoney.com/a/202603113668972521.html
By editor
Copyright©2026 Ddu. All rights reserved.
Read more on
- SHR-9803 for Injection Approved for Clinical Trials March 12, 2026
- Invests 5 million yuan to participate in the establishment of an investment fund to expand into the biopharmaceutical field March 12, 2026
- Huadong Medicine’s clinical trial application for injectable HDM2024 drug has been approved by the US FDA March 12, 2026
- Novogene® has been approved, making its global debut in China! March 10, 2026
- CSPC indacaterol mometasone inhalation powder has been approved for clinical trials in China. March 10, 2026
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
